PedAM
Pediatric Disease Annotations & Medicines
| Disease | gout |
| Phenotype | C0740394|hyperuricaemia |
| Sentences | 4 |
| PubMedID- 23741640 | Febuxostat is orally administered a non-purine, selective inhibitor of xanthine oxidase being developed for the management of hyperuricaemia in patients with gout (zhu et al. |
| PubMedID- 24821702 | hyperuricaemia) can lead to gout (2). |
| PubMedID- 24225170 | Potentially correctable persistent hyperuricaemia increases the risk of recurrent gout flares and there is also an association with increased cardiovascular morbidity [14,15]. |
| PubMedID- 21155617 | The nice appraisal committee concluded that febuxostat be recommended as an option for the management of chronic hyperuricaemia in gout only for people who are intolerant to allopurinol or for whom allopurinol is contraindicated. |
Page: 1